Cardio Diagnostics (CDIO)

The company’s approach centres on an AI-driven Multi-Omics Engine, which combines multiple layers of biological information rather than relying on a single marker. Epigenetics is a key part of this strategy because changes in gene expression can reflect the interaction between inherited risk, lifestyle, environment, and disease biology. Cardio Diagnostics applies these insights to create tests that may help identify patients at risk of serious cardiovascular events, including heart attacks.

Its commercial products include Epi+Gen CHD and PrecisionCHD. Epi+Gen CHD is positioned as an epigenetics-based blood test for assessing the risk of a coronary heart disease event. PrecisionCHD is also an epigenetics-based clinical blood test and is aimed at supporting evaluation of coronary heart disease. Together, these products reflect the company’s focus on precision medicine in cardiology, an area where earlier detection and better risk stratification can influence prevention and treatment decisions.

Beyond its clinical tests, Cardio Diagnostics has developed HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only tool for discovery, development, and validation work in biopharmaceutical research. The company operates in a market shaped by rising cardiovascular disease burden, growing interest in preventive diagnostics, and the challenge of gaining clinical adoption, reimbursement, and trust for new molecular testing technologies.